NOFLY has been recently approved for its trade in Israel as a biopesticide suitable for organic farming (ref. 7453) for the biological control of whiteflies, aphids and thrips, pathogenic insects that cause annually significant economic losses in crops worldwide.
This bioinsecticide based on spores of the strain FE9901 of the entomopathogenic fungus Isaria fumosorosea began to develop in 2001, came to its definitive formulation in 2005 and began its registration for commercialization in the US and Canada in 2008 and in the EU in 2013, after eight years waiting for its final approval.
Along with Israel, one of the most leading products of Futureco Bioscience, entirely developed and registered from Spain, it's also commercialized in the US, Canada, Morocco, Kenya, Belgium and Italy, and is under registration in the remaining twenty-five countries of the EU and in Latin American countries such as Mexico, Brazil, Argentina, Chile, Peru, Colombia, Ecuador, Guatemala, Dominican Republic and Costa Rica.
In addition to a European Union Prize of the Environment to Companies in the category of most innovative product in 2014, NOFLY is not only reaching achievements in the field of commercial regulation, but also of the Department of R&D of Futureco Bioscience, from which their effectiveness in pest whiteflies, aphids and thrips are constantly tested and their safety on beneficial insects and compatibility with integrated management programs that address the combination with other pest control techniques. A great example of environmental care, planning of crop protection respectful with the farmer and demonstration that perseverance and excellence in research is a safe bet.